By Fineline Cube 
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has successfully issued the nation’s first mid- to long-term technology innovation bond for the private pharmaceutical sector. The bond issue was led by China Merchants Bank as the lead underwriter and bookrunner, with Bank of Beijing and SPD Bank as joint underwriters. The bond has a size of 1 billion yuan, a 2-year term, and a coupon rate of 2.70%.
Funds Allocation
The proceeds from the bond will provide robust financial support for Fosun Pharma’s strategic initiatives in key technology innovation areas. This funding aims to accelerate the translation and commercialization of innovative research outcomes, further solidifying the company’s competitive edge in the global pharmaceutical and healthcare industry.
Innovative Drug Pipeline
Since 2019, Fosun Pharma has secured approval for a cumulative total of 12 self-developed and in-licensed innovative drugs and biosimilars. The company has also obtained commercialization rights in mainland China for eight innovative drugs across core therapeutic areas such as solid tumors, hematological tumors, and immune inflammation. From January to May 2025, five indications for four of Fosun Pharma’s products received approval in multiple regions, including China and the EU. This includes the marketing approval of its first self-developed small-molecule innovative drug, luvometinib, addressing a gap in rare tumor treatments. Additionally, its PD-1 monoclonal antibody, serplulimab, became the first PD-1 mAb approved in the EU for extensive-stage small cell lung cancer (ES-SCLC), marking significant progress in international expansion.-Fineline Info & Tech